This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone

Stephen R. Marder, MD; Robert Conley, MD; Larry Ereshefsky, PharmD, BCCP, FCCP; John M. Kane, MD; and Martin S. Turner, MB, BS

Published: November 1, 2003

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

The availability of a long-acting injectable atypicalantipsychotic may increase compliance with medication regimens in patients with schizophrenia. Currently,long-acting risperidone is the only such agent. It is nowavailable or approved in 33 countries, including Austria,Germany, Mexico, the Netherlands, New Zealand, and the United Kingdom.’ ‹’ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 64

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!


Already registered? Sign In

Original Research

Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

Prevalence and correlates of obsessive-compulsive symptoms and OCD were identified from the case records of over 22,500...